Introduction
Specific innate and adaptive immune mechanisms are emerging as key modulators of the effects of antibody-mediated tumoricidal activity in various types of cancer [1, 2] . For instance, in breast cancer, innate and acquired immune functions influence the efficacy of antihuman epidermal growth factor receptor-2 (HER2)-targeted antibody therapy in a preclinical model [3, 4] . In the clinical setting, anti-HER2 antibody treatment can remarkably improve the survival outcome of primary breast cancer patients with HER2-positive disease. However, it is also true that the therapeutic effect varies by tumor and by individual [5] .
Macrophages are a key subset of immune cells that regulate specific innate and adaptive immune responses [6] . Recent reports have shown that tumor-associated macrophages mediate various immune reactions, such as cytokine secretion, to support and/or inhibit cancer progression, which correlates with prognosis [7] [8] [9] . Neuropilin-1 (NRP-1) was initially characterized as a molecule that guides migrating cells and axons in the developing nervous system and is essential for the accurate formation of neurons and vasculature. Several reports have suggested that NRP-1 could be an important molecule for monocyte/macrophage regulation and relevant immune function in tumor microenvironments and that NRP-1-expressing macrophages might play an important role in antitumor activity in tumor microenvironments. NRP-1-expressing monocytes, defined as CD11b + Gr1
− , possess antitumoral properties [10] . Tordjman et al. reported that macrophages expressing NRP-1 were required for the initiation of primary T cell activation [11] . Casazza et al. found that the NRP-1 pathway is specifically up-regulated in hypoxic areas, where it entraps NRP-1-expressing macrophages, resulting in the accumulation of protumoral macrophages that drive tumor progression [9] . Ji et al. reported that NRP-1 expression is higher in M2 macrophages than in M1 macrophages [12] . Thus, the role of NRP-1 expression on macrophages in immune modulation in tumor microenvironments remains unclear.
To clarify the role of NRP-1 expression on macrophages in antibody-mediated antitumor immunity, here we investigated the impact of NRP-1 knockdown on macrophages and of anti-NRP-1 antibody treatment on antibody-dependent cellular cytotoxicity (ADCC) activity in vitro and also studied its impact on the antitumor immune response in a humanized mouse model of HER2-positive breast cancer.
Materials and methods

Cell lines
SKBR3 cells (HER2-overexpressing human breast cancer cell line) were obtained directly from the American Type Culture Collection (ATCC, Manassas, VA) on September 27, 2013 and passaged in our laboratory for fewer than 6 months after resuscitation. BT474 cells (HER2-overexpressing human breast cancer cell line, HTB-20) were also obtained directly from the ATCC on November 5, 2008 and passaged in our laboratory for fewer than 6 months after resuscitation. BT474 cells were cultured in DMEM containing 10% fetal bovine serum (FBS), and SKBR3 cells were cultured in RPMI 1640 medium containing 10% FBS.
To establish Gaussia luciferase (Gluc)-expressing BT474 cells (BT474 Gluc ), BT474 cells were transfected with a Gluc expression vector using polyethylenimine "MAX" (Polysciences, Warrington, PA) and selected using puromycin (Nacalai Tesque, Kyoto, Japan) to establish stable cell lines. The expression vector was constructed by cloning the Gluc coding region into the pCAGIPuro vector (kindly provided by Dr. H. Niwa, RIKEN). pCAGIPuro, an IRES-based bicistronic expression vector in which the gene of interest and a puromycin-resistant gene are expressed from a single mRNA, enables almost all puromycin-selected cells to express the gene product.
Preparation of PBMCs, monocytes, and macrophages
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were prepared using Vacutainer CPT Cell Preparation Tubes (BD Biosciences, Bedford, MA). Human peripheral blood monocytes were separated from peripheral blood using RosetteSep Human Monocyte Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) and magnetic-activated cell sorting with a Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch-Gladbach, Germany), according to the manufacturers' instructions. Although prior reports have shown that macrophage colony-stimulating factor is necessary for NRP-1 expression on dendritic cells and monocyte-derived macrophages [11] [12] [13] , our optimization experiments showed that it was not always required for an increase in NRP-1 expression on monocyte-derived macrophages (data not shown). In this study, human monocyte-derived macrophages were prepared from adherent monocytes after culture of PBMCs for 24 h in 24-well plates containing RPMI 1640 medium with 10% FBS, and macrophage-depleted PBMCs were prepared by retrieving the floating cells in those culture conditions.
Knockdown of NRP-1 on immune cells by siRNA
Control small interfering RNA (siRNA; Silencer Select Negative Control #1) and siRNA targeting NRP-1 (NRP-1 siRNA s16844 1: sense, 5′-GGUAUGGUGUCUGGACU-UATT-3′; antisense, 5′-UAAGUCCAGACACCAUAC-CCA-3′) (Applied Biosystems, Foster City, CA) were transfected into PBMCs or macrophages using Lipofectamine RNAiMAX (Life Technologies, Gaithersburg, MD) according to the manufacturer's protocols.
ADCC measurement
ADCC was measured using an LDH Cytotoxic Test Kit (Wako, Osaka, Japan), which has a sensitivity similar to that of the traditional Cr 51 assay [14] . In the ADCC assay, NRP-1-knocked down macrophages (Macrophages siNRP-1 ), control macrophages (Macrophages siNC ), monocytes, and PBMCs were used as effector cells, while SKBR3 cells were used as target cells. Trastuzumab or pertuzumab (Chugai Pharmaceutical Co., Tokyo, Japan) was used as the treatment antibody. The target-to-effector ratio was fixed at 10:1, and the incubation time was set at 24 h based on our optimization experiments (data not shown). ADCC activity was calculated according to the manufacturer's instructions. Cytotoxicity was calculated as % specific lysis = [(effector release − target release) − effector control release] − negative control/(positive control release − negative control release)] × 100. A human NRP-1 monoclonal antibody (AF3870; R&D Systems, Minneapolis, MN) was used to neutralize NRP-1, and IgG (R&D Systems) was used as a control antibody in the ADCC assay.
Humanized mouse model of HER2-positive breast cancer
Female NOD/Shi-scid, IL-2Rγ null (NOG) mice were obtained from the Central Institute for Experimental Animals (Kawasaki, Japan) and used at 6 weeks of age. In vivo experiments were conducted in accordance with the United Kingdom Coordinating Committee on Cancer Research and Guidelines for the Welfare of Animals in Experimental Neoplasia (second edition).
The tumor-bearing NOG mouse model was created using BT474
Gluc cells as follows. Briefly, BT474 Tumor specimens were harvested on day 28, and one half of the tumor sample was preserved by formalin fixation, and the other half was immediately placed in liquid nitrogen for RNA and protein extraction.
For the model of NRP-1 knockdown on macrophages, 30 tumor-bearing mice were divided into five treatment groups of six animals each such that the mean RLU were equal in each group. The following treatments were given: (i) control (saline) 
Tumor volume monitoring
The greatest longitudinal diameter (length) and greatest transverse diameter (width) were measured with a caliper. Tumor volume was calculated using the ellipsoidal formula as follows: tumor volume = 1/2(length × width 2 ). We also assessed viable tumor cells by measuring the activity of secreted Gluc in the blood. Measurement of blood Gluc was performed as described previously [15] [16] [17] . Briefly, blood samples were diluted with phosphate-buffered saline (PBS) containing 0.02% Tween 20 and 20 mM ethylenediaminetetraacetic acid (EDTA) and stored at −80 °C until use. The luminescence of the diluted blood samples (0.02% Tween 20/20 mM EDTA/PBS buffer) was determined using a Centro LB 960 microplate luminometer (Berthold Technologies, Bad Wildbad, Germany). A reaction mixture containing coelenterazine (final concentration 1 µg/100 µL) in PBS plus 0.02% Tween 20 and 20 mM EDTA was injected into the wells of a plate that was placed into the instrument, and luminescence intensity was recorded at 0.1-s intervals for 10 s or 10 min. Data are expressed as maximum luminescence intensity (I max ) in RLU, and the change in RLU was calculated as follows:
RLU % change = [(RLU on day 21 or 28 − RLU on day 14)/RLU on day 14] × 100
RNA extraction and qRT-PCR
Quantitative real-time PCR (qRT-PCR) was performed with TaqMan Fast Virus 1-step Master Mix (Life Technologies) and TaqMan gene expression probes for NRP-1 (Assay ID: Hs00826128_m1), CD4 (Assay ID: Hs01058407_m1), CD8 (Assay ID: Hs00233520_m1), and CD45 (Assay ID: Hs04189704_m1) (Life Technologies).
RNA sequencing
Platelet RNA-Seq analysis was performed on an Ion Proton System for next-generation sequencing (Life Technologies). For each of the samples, 10 ng total RNA was reverse transcribed using an Ion AmpliSeq Transcriptome Human Gene Expression Kit (Life Technologies) following the manufacturer's protocol.
Flow cytometry
PBMCs from healthy volunteers were stained with fluorescein isothiocyanate-conjugated antihuman CD3 (clone UCHT1; Abnova, Taipei, Taiwan), anti-CD4 (clone RPA-T4; BioLegend, San Diego, CA), anti-CD14 (clone 61D3; eBioscience, San Diego, CA), and allophycocyanin-conjugated anti-NRP-1 allophycocyanin monoclonal antibodies (clone 446921, R&D Systems).
Cytokine measurements
The cytokines interleukin (IL)-1β, IL-1γα, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor (GCSF), interferongamma (IFN-γ), monocyte chemoattractant protein-1, macrophage inflammatory protein-1α (MIP-1α), macrophage inflammatory protein-1β (MIP-1β), platelet-derived growth factor-BB, RANTES, vascular endothelial growth factor (VEGF), fibroblast growth factor, and tumor necrosis factor α (TNF-α) from the supernatants of macrophages incubated for 24 h were measured on a Bio-Plex multiplex assay system (Bio-Rad, Hercules, CA) according to the manufacturer's instructions. Lysates of whole tumor samples were also prepared using a Bio-Plex lysis kit (Bio-Rad) according to the manufacturer's instructions, and the levels of various cytokines in the tumor lysates were measured on a Bio-Plex multiplex assay system.
Immunohistochemistry
The primary antibodies used for immunohistochemistry and immunofluorescence are listed in Supplemental Table S1 . For immunohistochemistry, the sections were incubated with MACH 2 Double Stain 2 (Biocare Medical, Walnut, CA), EnVision HRP (K4001; Dako, Burlingame, CA), or Simple Stain AP (414251; Nichirei Bioscience, Tokyo, Japan) for 1 h.
Evaluation of TILs
Histopathologic assessment of the percentage of tumor-infiltrating lymphocytes (TILs) was performed on one representative immunohistochemical section of a tumor using methods recommended by the International TILs Working Group 2014 [18] . % TILs was defined as the percentage of lymphocyte area per tumor area in vivo samples. Areas of in situ carcinomas, normal lobules, necrosis, hyalinization, and crush artifacts were not included. Histopathologic evaluation of TILs was performed by two breast pathologists who scored each case independently in a blind manner. The mean values of both observers were obtained as the final scores for each case.
Human samples
All samples from healthy volunteers were collected in the Department of Breast Surgery, Kyoto University Hospital. Written informed consent was obtained from all participants prior to sample collection. All study protocols were approved by the Ethics Committee for Clinical Research, Kyoto University Hospital (authorization number G424).
Statistical analysis
The significance of differences between groups was determined by an unpaired two-tailed Student's t test or MannWhitney test. Results were considered statistically significant at p < 0.05. Data were analyzed with STATA version 13.0.
Results
NRP-1 expression on monocytes and macrophages
Previous investigations suggested that NRP-1 is expressed mainly on dendritic cells and monocyte-derived macrophages, but not on monocytes [11, 12] . We used flow cytometry to identify NRP-1-expressing immune cells in samples obtained from healthy volunteers. NRP-1 was expressed primarily on macrophages, but its expression was minor in CD3 (Fig. 1a, b) . Next, we examined the genetic characteristics of monocytes and macrophages using RNA sequencing (GEO accession: GSE75428). NRP-1 was included in the top 100 up-regulated genes in macrophages as compared with monocytes ( Fig. 1c and Supplemental Table S2 ). In macrophages, CD14, a monocyte marker that is downregulated during monocyte-macrophage differentiation was downregulated compared with monocytes. Conversely, CD68 and CD84, which are representative markers of macrophages, were up-regulated in macrophages (Fig. 1c) . Up-regulation of NRP-1 expression on macrophages was also confirmed by qRT-PCR and western blotting (Fig. 1d, e) .
3
ADCC activity and cytokine secretion are suppressed by NRP-1 inhibition in vitro
We investigated the role of NRP-1 expression on macrophages with respect to ADCC, which is one of the major mechanisms of antibody-mediated tumoricidal activity [19] . In this study, we used Macrophages siNRP-1 and Macrophages siNC as effector cells. As the mRNA levels of NRP-1 were raised immediately after seeding on cell culture dishes (Supplemental Figure S2a) , NRP-1 knockdown was performed by siRNA administration to fresh monocytes or fresh PBMCs. The average knockdown efficiency was ~65% after 24 h, suggesting that the siRNA used could strongly inhibit NRP-1 expression on monocytes (Supplemental Figure S2b, c) . The LDH assay showed that Macrophages siNRP-1 suppressed ADCC activity significantly as compared with Macrophages siNC in both SKBR3 and BT474 cells (Fig. 2a, e) , and ADCC activity mediated by macrophages was higher than ADCC activity mediated by monocytes in SKBR3 cells (Fig. 2b) . Macrophage-induced ADCC activity was also suppressed by the NRP-1-neutralizing antibody in both SKBR3 and BT474 cells (Fig. 2c,  f) . PBMC-induced ADCC activity was also suppressed by the NRP-1-neutralizing antibody in SKBR3 cells, but not in BT474 cells (Fig. 2d, g ).
Several cytokines augment ADCC by direct activation of immune cells or by enhancement of tumor-associated antigens on tumor cells [20] . Therefore, we tested chemokine secretion in the presence of the NRP-1-neutralizing antibody. The secretion of cytokines by NRP-1-expressing macrophages was suppressed by the NRP-1-neutralizing antibody in vitro (Fig. 2h and raw data in Supplemental Table S3 ). Additionally, VEGF165, which is a ligand of NRP-1, enhanced the secretion of proinflammatory cytokines from macrophages, such as IP-10, TNF-α, IFN-γ, IL-12, and GCSF. Interestingly, this secretion was suppressed by the NRP-1-neutralizing antibody, while protumoral cytokines, such as IL-1α and IL-10, were not suppressed by treatment with the NRP-1-neutralizing antibody (Supplemental Figure S1) .
Knockdown of NRP-1 on PBMCs suppresses anti-HER2 antibody-mediated tumoricidal activity in a humanized mouse model
We further investigated the role of NRP-1 in ADCC in a humanized mouse model with HER2-positive tumors. For this experiment, we used an established humanized mouse model, namely NOG mice [21, 22] . Tumor volume was estimated by measuring the luminescence intensity of peripheral blood from humanized NOG mice transplanted with cancer cells expressing secreted luciferase [17] . We generated luciferase-secreting breast cancer cells by transfection with an expression vector encoding the secreted luminescent protein of Gaussia princeps. As BT474 cells show better tumorigenicity than SKBR3 cells, we used BT474 cells in the mouse model. BT474
Gluc cells were inoculated into the fat pads of NOG mice, and peripheral blood taken from the tail vein was analyzed for luminescence. Luminescence intensity correlated well with the number of transplanted cells, with a linear range covering over seven orders of magnitude (Supplemental Figure S4a) . NRP-1 on PBMCs was knocked down by siNRP-1 before injection via the tail vein. Knockdown efficiency was approximately 65%, and almost all knocked-down cells were macrophages (Supplemental Figure S2b -e). The treatment schema is shown in Supplemental Figure S4b . Relative luminescence between day 21 or 28 and day 14 was evaluated. On day 28, the trastuzumab plus PBMC siNC treatment group showed remarkable inhibition of tumor growth; however, the trastuzumab plus PBMC siNRP-1 group showed only a limited effect that was similar to the trastuzumab alone group, indicating that NRP-1 expression on PBMCs is closely involved with the enhancement of ADCC activity (median: −36.3 vs. 56.3%, p = 0.035, Mann-Whitney test) (Fig. 3a-d) .
To clarify the role of NRP-1-expressing macrophages more precisely, we replaced the macrophages in PBMCs with NRP-1-knocked down macrophages (adding Macrophages siNRP-1 or Macrophages siNC into macrophage-depleted PBMCs) and tested the efficacy of such PBMCs in the mouse model described above (Fig. 3e, f) . The antitumor effect of trastuzumab plus PBMCs with Macrophages siNRP-1 was significantly reduced as (0, 0.1, 1 , and 10 µg/mL). g PBMCs were co-cultured with target BT474 cells and trastuzumab with anti-NRP-1 antibodies (0, 0.1, 1, and 10 µg/ mL). The concentration of trastuzumab and pertuzumab was 1 μg/ mL, and the effector-to-target ratio was 10:1. N = 3 for all experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns not significant. All graphs show mean ± SEM. h The effect of the NRP-1-neutralizing antibody on the secretion of 27 cytokines was evaluated and shown by heat map display. Fold change of cytokine expression following NRP-1 inhibition compared to the control group is shown by yellow-to-blue color graduation. (Raw data are shown in Table S1 .)
compared with that of trastuzumab plus PBMCs with Macrophages siNC (mean: −39.6% vs. 17.7%, p = 0.0048, Mann-Whitney test), further supporting the hypothesis that NRP-1-expressing macrophages play an important role in anti-HER2 antibody-mediated antitumor activity by cooperating with other subsets of immune cells.
Knockdown of NRP-1 on macrophages suppresses lymphocyte infiltration into tumors
Recent reports have shown that anti-HER2 antibodymediated tumoricidal activity is associated with TILs in breast cancer [18, 23] . We investigated the interaction between NRP-1 knockdown and TILs in the humanized mouse model. TILs were identified by immunohistochemical staining and qRT-PCR for CD45, CD4, and CD8, which have no cross-reactivity with mouse immune cells. Injection of human PBMC siNC with trastuzumab yielded much more CD45-positive TILs as compared with the PBMC alone group, and such an increase in TILs was inhibited in the PBMC siNRP-1 group (Fig. 4a) . Next, we examined the characteristics of CD45 + TILs by immunohistochemistry (Fig. 4b) and qRT-PCR (Fig. 4c) . Most of the CD45 + TILs were positive for CD4 and a small proportion expressed CD8 (Fig. 4c) . Lower levels of CD45 transcripts were observed in the PBMC siNRP-1 group compared with the PBMC siNC group (Fig. 4c) . Relative quantities of human CD4 mRNA, but not human CD8 mRNA, were also decreased in the PBMC siNRP-1 group (Fig. 4c) . We then investigated whether the expression of NRP-1 on macrophages affected the production of various cytokines in vivo. The expression of IP-10, RANTES, MIP-1α, and MIP-1β in tumor samples was suppressed in the NRP-1-knocked down group (Fig. 4d) . IP-10, RANTES, MIP-1α, and MIP-1β are mainly secreted from M1 macrophages, which may be attributed to the chemoattraction of CD4 + T cells to tumor sites and enhanced antitumor activity. These results suggested that NRP-1-expressing immune cells, especially macrophages, might play an important role in the migration of CD4-positive immune cells into tumors.
Discussion
ADCC is considered one of the main mechanisms of the antibody-mediated antitumor immune response and is mediated by effector cells such as natural killer cells, monocytes, and macrophages [24] . In this study, we confirmed the importance of macrophages in ADCC activity, while monocytes showed little ADCC activity in our assay (Fig. 2a-g ). A recent report showed that tumorderived semaphorin 3A, which is one of the ligands of NRP-1, augmented the production of antitumoral cytokines, such as IP-10, TNF-α, IFN-γ, and IL-12, and restricted the production of protumoral cytokines, such as IL-1α and IL-10, by macrophages [25] . While various mechanisms regulating macrophage function have been reported, this suggested that the NRP-1 signal in macrophages is one of the important signals for the induction of antitumor immune responses. It was also reported that antitumoral cytokines, such as IL-2, IL-12, TNF-α, and IFN-γ, which are representative Th1 cytokines, enhanced ADCC activity [20] . Thus, our findings that inhibition of NRP-1 on macrophages suppressed the secretion of antitumoral cytokines, such as IP-10, TNF-α, and IFN-γ (Fig. 2h) , and that the VEGF165-induced secretion of IL-1α, IL-10, IP-10, TNF-α, IFN-γ, and IL-12 was suppressed by the anti-NRP-1 antibody (Supplemental Figure S1 ), might explain why NRP-1 knockdown on macrophages suppressed ADCC activity in vitro (Fig. 2a, e) and in our mouse model (Fig. 3a-f) .
Regulation of M1 and M2 macrophages in the breast cancer microenvironment is important in antitumor immunity. NRP-1 expression is higher in M2 macrophages than in M1 macrophages (Supplemental Figure  S3a) [12, 25] , suggesting that NRP-1 expression plays an important role in the polarization of M2 macrophages. Conversely, we confirmed that the cytokines secreted mainly by M1 macrophages are suppressed when NRP-1 was inhibited by neutralizing antibodies (Fig. 2h) . Wallerius et al. reported that SEMA3A induced the proliferation of M1 macrophages, which resulted in the increased phosphorylation of Akt and MAPK through NRP-1 [25] . Thus, it is suggested that NRP-1 might play an important role in M1 macrophages in terms of their antitumor immunity. Further study will be needed to resolve the roles of NRP-1 in macrophages.
The presence of TILs is associated with better outcomes in patients with various types of cancer who receive adjuvant or neoadjuvant antibody agent-based systemic therapy [23, 26, 27] . The precise analysis of TIL subsets could be important to understand the role of TILs in tumor microenvironments. Our study showed that NRP-1 knockdown suppressed the infiltration 
of CD45
+ immune cells into tumors in a humanized mouse model (Fig. 4a, b) . Importantly, the infiltration of CD4 + cells into tumors was significantly suppressed by NRP-1 knockdown on PBMCs (Fig. 4c) . Macrophages are reported to produce chemokines, including IP-10, MIP-1α, MIP-1β, and RANTES, to attract CD4 + T cells [28, 29] . CD4 + T cells exert their anticancer actions by providing help to CD8 + T cells followed by the secretion of type 1 cytokines or direct tumor killing [30] [31] [32] . These observations and our findings indicate that NRP-1 on macrophages may regulate CD4 + T cell infiltration into tumors and modulate adaptive immune responses in addition to antibody-mediated innate tumoricidal activity.
We acknowledge that this study has several limitations. In particular, the immune cells used were collected from healthy volunteers and allogenic antitumor immune reactions were not excluded completely. However, because it has been suggested that the functions of NRP-1 are different between human and mouse immune cells, we used the humanized mice model in this study in order to try to elucidate a role for NRP-1 in human macrophages even if allogenic effects could exist. Another limitation would be that an extended time course analysis of the role of NRP-1 in macrophages in this humanized mice model was not conducted. As NRP-1 expression in siNC PBMCs almost disappeared within 96 h due to the difficulty of maintaining the viability of PBMCs in long-term culture without stimulation in vitro, it is difficult to evaluate how long NRP-1 knockdown lasts in macrophages (Supplemental Figure  S2f) . However, it is known that the knockdown effect of siRNA lasts for approximately 5 days, and NRP-1 expression would be restored thereafter; therefore, NRP-1 in macrophages might mainly function in the acute setting of antitumor activity in vivo. Further research will be needed to elucidate this issue.
In conclusion, we demonstrated that NRP-1 expression on macrophages is required for antibody-mediated tumoricidal activity and CD4 + T cell infiltration into tumor sites by performing in vitro and in vivo experiments with a human breast cancer xenograft model. We propose that regulation of the NRP-1 pathway in macrophages may induce an antitumor immune response by creating a favorable tumor microenvironment, and the presence of tumor-infiltrating NRP-1-expressing immune cells may be beneficial for producing a better response. In addition, NRP-1 expression on macrophages may be a therapeutic indicator for antibody treatments exerting ADCC activity, although further studies are needed to support this hypothesis. Fig. 4 Knockdown of NRP-1 on PBMCs suppresses lymphocyte infiltration into tumors. a CD45 staining of tumor tissues in each group is shown (scale bar, 100 µm). b Population of % TILs in five groups. TILs were defined as % CD45-positive cells in the invasive tumor area. N = 3-4. *p < 0.05, **p < 0.01, ***p < 0.001. All graphs show mean ± SEM. c Upper CD45, CD4, and CD8 staining of tumor tissues in PBMC siNC + Trastuzumab group is shown (scale bar, 100 µm). Lower CD45, CD4, and CD8 mRNA expression of tumor tissues in each group in day 28 tumors is shown. N = 3-4. *p < 0.05, **p < 0.01, ***p < 0.001, ns not significant. All graphs show mean ± SEM. d Secretion of IP-10, RANTES, MIP-1α, and MIP-1β from tumor samples was suppressed by NRP-1 knockdown. N = 3-4. *p < 0.05. All graphs show mean ± SEM ◂
